Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: review and recommendations

• Published in: Cancer imaging Vol. 20; no. 1; pp. 34 - 13
• Main Authors: Zugni, Fabio, Padhani, Anwar Roshanali, Koh, Dow-Mu, Summers, Paul Eugene, Bellomi, Massimo, Petralia, Giuseppe
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.05.2020; BioMed Central; BMC
• Subjects: Abnormalities; Cancer; Cancer research; Cancer screening; Consortia; Diagnostic imaging; Early Detection of Cancer - methods; Humans; Incidental findings; Lymphoma; Magnetic resonance imaging; Magnetic Resonance Imaging - methods; Medical imaging; Medical research; Medical screening; Melanoma; Metastasis; Morphology; MRI; Multiple myeloma; Neoplasms - diagnostic imaging; Oncology; Population; Practice Guidelines as Topic; Prostate cancer; Review; Surveillance; Tomography; Tumors; Whole Body Imaging - methods; Whole body screening; Whole-body imaging; Womens health; Whole body screening; Magnetic resonance imaging; MRI; Whole-body imaging; Incidental findings; Cancer screening
• ISSN: 1470-7330; 1740-5025; 1470-7330
• DOI: 10.1186/s40644-020-00315-0

The number of studies describing the use of whole-body magnetic resonance imaging (WB-MRI) for screening of malignant tumours in asymptomatic subjects is increasing. Our aim is to review the methodologies used and the results of the published studies on per patient and per lesion analysis, and to provide recommendations on the use of WB-MRI for cancer screening. We identified 12 studies, encompassing 6214 WB-MRI examinations, which provided the rates of abnormal findings and findings suspicious for cancer in asymptomatic subjects, from the general population. Eleven of 12 studies provided imaging protocols that included T1- and T2-weighted sequences, while only five included diffusion weighted imaging (DWI) of the whole body. Different categorical systems were used for the classification and the management of abnormal findings. Of 17,961 abnormal findings reported, 91% were benign, while 9% were oncologically relevant, requiring further investigations, and 0.5% of lesions were suspicious for cancer. A per-subject analysis showed that just 5% of subjects had no abnormal findings, while 95% had abnormal findings. Findings requiring further investigation were reported in 30% of all subjects, though in only 1.8% cancer was suspected. The overall rate of histologically confirmed cancer was 1.1%. WB-MRI studies of cancer screening in the asymptomatic general population are too heterogeneous to draw impactful conclusions regarding efficacy. A 5-point lesion scale based on the oncological relevance of findings appears the most appropriate for risk-based management stratification. WB-MRI examinations should be reported by experienced oncological radiologists versed on WB-MRI reading abnormalities and on onward referral pathways.